Home
Alembic Pharmaceuticals Share Price Traget 2025, 2026 to 2030

Alembic Pharmaceuticals Share Price Traget 2025, 2026 to 2030

Price Target January 26, 2025 0
Tweet
Share
Pin
Share
0 Shares

Alembic Pharmaceuticals Ltd., founded in 1907 and based in Vadodara, Gujarat, is a leading Indian multinational pharmaceutical company specializing in APIs, formulations, and biopharmaceuticals. With a global footprint in over 100 countries, including the US and Europe, the company is renowned for its innovation-driven R&D and world-class manufacturing facilities approved by global regulators like the US FDA. Alembic’s diverse portfolio includes generics, specialty drugs, and biotech products. Key milestones include expanding oncology and dermatology portfolios in 2019 and introducing biopharmaceuticals in 2021. Committed to sustainability and CSR, Alembic continues to excel in delivering quality healthcare solutions globally.

Recent News on Alembic Pharmaceuticals

Alembic Pharmaceuticals has achieved a significant milestone with USFDA approval for its generic version of Brexpiprazole tablets, used to treat major depressive disorder and schizophrenia. The approval spans strengths ranging from 0.25 mg to 4 mg, enabling the company to tap into a lucrative market valued at approximately USD 2 billion annually. This development underscores Alembic’s strong R&D capabilities and its commitment to delivering affordable, high-quality medications in the global pharmaceutical market.

Shareholdings Patterns of Alembic Pharmaceuticals

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters +69.61%69.61%69.61%69.61%69.61%
FIIs +4.52%4.46%4.32%3.94%4.17%
DIIs +14.51%15.39%15.47%16.05%16.05%
Public +11.36%10.54%10.61%10.38%10.17%
No. of Shareholders85,21276,56774,82991,42993,944

Alembic Pharmaceuticals’ shareholding pattern reflects stability in promoter holdings and dynamic shifts among institutional and public investors throughout 2024. Promoters consistently held a significant 69.61% stake, underscoring strong ownership confidence. Foreign Institutional Investors (FIIs) exhibited a slight decline from 4.52% in December 2023 to 4.17% by December 2024, while Domestic Institutional Investors (DIIs) increased their holdings from 14.51% to 16.05%, showcasing rising domestic interest. Public shareholding gradually decreased from 11.36% to 10.17% over the same period. Notably, the number of shareholders grew from 85,212 in December 2023 to 93,944 by December 2024, indicating broader investor participation in Alembic Pharmaceuticals.

How to Purchase Alembic Pharmaceuticals Shares in India?

Below are the trading platforms that you can use to purchase Alembic Pharmaceuticals shares:

➤ Zerodha

➤ Upstox

➤ Groww

➤ AngelOne

➤ ICICIDirect

Alembic Pharmaceuticals Share Price Prediction 2025 – 2030

Alembic Pharmaceuticals Share Price Target 2025

WhenMaximum PriceMinimum Price
February 20251,018.59783.53
March 20251,039.98799.98
April 20251,029.68792.06
May 2025999.69768.99
June 20251,044.68803.60
July 20251,024.19787.84
August 20251,055.87812.21
September 20251,068.54821.95
October 20251,096.32843.33
November 20251,123.73864.41
December 20251,174.30903.31

As we move through 2025, Alembic Pharmaceuticals is projected to exhibit strong price movements. Starting in February, the maximum price is expected to reach ₹1,018.59, while the minimum could be ₹783.53. By December, Alembic Pharmaceuticals is anticipated to peak at ₹1,174.30, with a minimum of ₹903.31, highlighting a consistent upward trend throughout the year.

Finances rule

Alembic Pharmaceuticals Share Price Prediction 2026

WhenMaximum PriceMinimum Price
January 20261,209.53930.41
February 20261,179.29907.15
March 20261,202.88925.29
April 20261,227.42944.17
May 20261,215.27934.82
June 20261,245.65958.19
July 20261,221.23939.41
August 20261,259.00968.46
September 20261,284.18987.83
October 20261,317.571,013.51
November 20261,350.511,038.85
December 20261,384.271,064.82

As we progress through 2026, Alembic Pharmaceuticals is projected to show remarkable price growth. In January, the maximum price is expected to reach ₹1,209.53, with a minimum of ₹930.41. By December, the stock is anticipated to climb further, with a maximum price of ₹1,384.27 and a minimum of ₹1,064.82.

Alembic Pharmaceuticals Share Price Prediction 2027

WhenMaximum PriceMinimum Price
January 20271,398.111,075.47
February 20271,433.961,103.05
March 20271,489.881,146.07
April 20271,460.671,123.59
May 20271,418.131,090.87
June 20271,481.941,139.96
July 20271,452.891,117.60
August 20271,497.821,152.17
September 20271,550.241,192.50
October 20271,590.551,223.50
November 20271,630.311,254.09
December 20271,671.071,285.44

Alembic Pharmaceuticals Share Price Target 2028

WhenMaximum PriceMinimum Price
January 20281,704.491,311.15
February 20281,748.201,344.77
March 20281,816.381,397.21
April 20281,780.761,369.82
May 20281,728.901,329.92
June 20281,806.701,389.77
July 20281,771.271,362.52
August 20281,826.051,404.66
September 20281,889.961,453.82
October 20281,939.101,491.62
November 20281,987.581,528.91
December 20282,037.271,567.13

Alembic Pharmaceuticals Share Price Target 2029

WhenMaximum PriceMinimum Price
January 20292,078.021,598.47
February 20292,131.301,639.46
March 20292,214.421,703.40
April 20292,171.001,670.00
May 20292,107.771,621.36
June 20292,202.611,694.32
July 20292,159.431,661.10
August 20292,226.211,712.47
September 20292,304.131,772.41
October 20292,364.041,818.49
November 20292,423.141,863.95
December 20292,483.721,910.55

Alembic Pharmaceuticals Share Price Target 2030

WhenMaximum PriceMinimum Price
January 20302,533.391,948.76
February 20302,598.351,998.73
March 20302,699.692,076.68
April 20302,646.752,035.96
May 20302,569.661,976.66
June 20302,685.302,065.61
July 20302,632.642,025.11
August 20302,714.062,087.74
September 20302,809.062,160.81
October 20302,882.092,216.99
November 20302,954.142,272.42
December 20303,028.002,329.23

In 2030, Alembic Pharmaceuticals is anticipated to demonstrate substantial price growth. In January, the stock’s maximum price is projected to reach ₹2,533.39, with a minimum of ₹1,948.76. By December, the upward trajectory is expected to continue, with the maximum price climbing to ₹3,028.00 and the minimum reaching ₹2,329.23

Financial Condition of Alembic Pharmaceuticals

Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales +4,6065,3935,3065,6536,2296,357
Expenses +3,3833,9134,4324,9705,2965,355
Operating Profit1,2231,4808746829321,002
OPM %27%27%16%12%15%16%
Other Income +-398756-22839
Interest271618505658
Depreciation157183287275273278
Profit before tax1,0001,368625355632705
Tax %20%19%17%4%3%
Net Profit +8011,146521342616646
EPS in Rs43.9758.3326.517.431.3332.9
Dividend Payout %23%24%38%46%35%

Alembic Pharmaceuticals has showcased a dynamic financial trajectory over the years, reflecting its ability to navigate challenges while expanding its operations. Between March 2020 and the trailing twelve months (TTM), the company’s sales grew from ₹4,606 crore to ₹6,357 crore, highlighting its commitment to scaling its revenue streams. However, rising expenses, which increased from ₹3,383 crore to ₹5,355 crore during the same period, have influenced profitability margins. Despite these challenges, the company maintained a resilient performance, supported by its diversified product portfolio and operational capabilities.

Operating profit trends have been mixed, with a peak of ₹1,480 crore in March 2021, followed by a dip to ₹682 crore in March 2023, before rebounding to ₹1,002 crore in the TTM. The Operating Profit Margin (OPM) mirrored this pattern, declining from 27% in March 2021 to a low of 12% in March 2023, and stabilizing at 16% in the TTM. Despite fluctuations in other income and rising interest and depreciation expenses, Alembic Pharmaceuticals demonstrated a commendable recovery in profit before tax, improving from ₹355 crore in March 2023 to ₹705 crore in the TTM. Similarly, net profit rebounded from ₹342 crore in March 2023 to ₹646 crore, indicating the company’s resilience and effective cost management.

Earnings per share (EPS) have shown a similar trend, peaking at ₹58.33 in March 2021 before settling at ₹32.9 in the TTM. Dividend payouts have remained strong, reaching 46% in March 2023, underscoring Alembic Pharmaceuticals’ commitment to rewarding its shareholders. Despite challenges in maintaining consistent margins, the company’s financial performance reflects its ability to adapt and grow, positioning itself as a key player in the pharmaceutical industry.

FAQs

What is Alembic Pharmaceuticals current market capitalization?

Alembic Pharmaceuticals current market capitalization is ₹18,672 Crores.

What is the current share price target for Alembic Pharmaceuticals?

The current share price target for Alembic Pharmaceuticals is ₹950.

What is Alembic Pharmaceuticals share price target for 2025?

Alembic Pharmaceuticals share price targets for 2025 range from ₹903.31 to ₹1,174.30 by December.

What is Alembic Pharmaceuticals share price target for 2030?

Alembic Pharmaceuticals share price targets for 2030 range from ₹1,948.76 to ₹3,028.00.

What is the current Price/Earnings (P/E) ratio of Alembic Pharmaceuticals?

Alembic Pharmaceuticals current Price/Earnings (P/E) ratio is 29.3.

Also Read

Concluding Insights: Alembic Pharmaceuticals Path to Success

In conclusion, Alembic Pharmaceuticals has established itself as a resilient and innovative leader in the pharmaceutical industry. With a strong focus on R&D and a diversified product portfolio, the company continues to grow its global presence, backed by strategic milestones like the expansion into oncology, dermatology, and biopharmaceuticals. Despite challenges such as fluctuating operating margins and increasing expenses, Alembic has demonstrated the ability to recover and achieve consistent revenue growth.

The shareholding patterns reflect stability, with strong promoter confidence and rising domestic institutional interest. Future share price predictions indicate a robust growth trajectory, with steady increases anticipated through 2030, culminating in a maximum projected price of ₹3,028.00. Alembic’s financial performance showcases its adaptability and commitment to delivering shareholder value while maintaining its leadership in delivering high-quality, affordable healthcare solutions worldwide.

Financesrule telegram

Author: Ashnoor

Related

Leave a Reply